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Abstract. The accumulation of amyloid- (A) peptide is one of the major neuropathological hallmarks of Alzheimer’s disease
(AD). We have analyzed whether the progression of amyloidosis differentially affects males and females along aging in APP/PS1
transgenic mice. The levels of peripheral amyloid, A40 and A42, are not modified in either sex until 9 months of age. After
that, however, there is an increase in amyloid levels in plasma among females and a decrease among males. These findings could
be essential to design gender-specific strategies in other in vivo experiments or even in AD treatments.
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Alzheimer’s disease (AD) is the most common
neurodegenerative disorder characterized by two
pathological features in the brain, extracellular amy-
loid plaques and intracellular neurofibrillary tangles [1,
2]. Most of AD cases are sporadic (unknown cause);
however a minor population of AD is from genetic
origin, known as familial AD and related to any muta-
tion in the amyloid- protein precursor (APP) [3],
Presenilin 1 [4], or Presenilin 2 [5]. In the study of
AD and in order to find therapies, different transgenic
mouse models expressing APP and/or PS1/2 human
mutations have been reported. These transgenic mice
accumulate A as diffuse neuritic plaques [6]. These
models are a useful tool for evaluating the effects of
potential therapeutic drugs designed to target A, even
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though the tau pathology is not completely reflected in
these models [7–9].
The initial mechanisms of pathology in sporadic AD
remain unclear, however, some risk factors have been
reported with age a strong one (see i.e., [10, 11]). Epi-
demiological studies show an increased risk of AD with
the age-related loss of sex steroid hormones. Clinical
studies have shown that females present an increased
risk of developing AD when compared with males
[12–14].
Our aim in the present study is to evaluate whether
a double-transgenic (APP/PS1) mouse model pre-
sented differences associated with aging and/or gender.
Thus, we have analyzed A production and accumu-
lation; and some additional brain markers over the
life-span of APP/PS1 mice [15], evaluating males and
females separately.
A40 and A42 levels have been analyzed in brain
tissue and in peripheral circulation (blood/plasma). It
has been suggested that A is kept in equilibrium
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between brain and blood through the blood-brain bar-
rier, and that peripheral sequestration of A may shift
this equilibrium from the brain, which can reduce A in
the brain following a reduction in the levels in periph-
eral blood ("sink” effect) [7, 8]. As a general procedure,
one hemibrain was snap frozen for subsequent homog-
enization either by ELISA or Western blot and the
other fixed for histology studies (more detail in Sup-
plementary Material) [16]. Blood samples were taken
by submandibular vein puncture [17] to isolate plasma
fraction in EDTA.
The levels of A40 and A42 in plasma showed
important differences between males and females
(Fig. 1A, B). The concentration of A40 in female
plasma from 3 to 15 months increased by more than
80%, while it decreased by 40% in males. The old-
est mice tested, 15 months, showed that the levels of
A40 in females were more than 4-fold higher than in
males. In the analysis of A42, slighter differences were
found; A42 levels in female plasma were 25% more
abundant at 15 months than at 3 months. Meanwhile,
male levels decreased by nearly 20% from 3 months
to 15 months. Older mice showed that females’ plasma
levels were 1.3 times higher than in males (p = 0.007)
at 15 months. Some previous reports had found that
APP23 transgenic mice didn’t show any differences
in the concentration of A in plasma with age [18].
However, other studies with APPTg2576 strain males
confirmed our findings [19]. Nevertheless, this is the
first time age-associated differences in plasma A lev-
els are described between males and females.
The A42/A40 ratio is another important marker
that may reflect cognitive decline and neurodegener-
ation [20, 21]. This value showed gender differences
in mice older than 12 months. The A42/A40 ratio
changes with age from 3 to 15 months: it is nearly
30% higher in males and more than 50% lower in
females (Fig. 1C). Higher toxicity has been described
at higher A42/A40 ratios in cultured neurons [21],
as has a relationship between lower levels of A42 and
A42/A40 ratio in plasma and the progression of AD
[22]. The difference between A42/A40 has been seen
by some authors as confirmation that A42 deposition
precedes A40 and that all A-positive plaques include
A42 but do not necessarily contain A40 [23].
All these data are really important and must be taken
into account in all experiments designed with these
transgenic mice in any therapeutic assay designed or
to be designed. Of course, these results make it imprac-
ticable to mix sexes in any assay with mice older than
10–12 months, particularly if the studies are testing the
level of A in plasma.
APP/PS1 mice showed A plaques in the brain
from 3 months of age (diffuse plaques) and levels were
highest at 12–15 months of age [24]. We have checked
the levels of A40 in a large number of brain samples
(37 males and 33 females), from one to 15 months
with the same ELISA kit used in plasma analysis.
There were no statistically significant differences (gen-
der related) along the life-span analyzed. However, the
increase in the concentration seemed to be faster in
females, reaching the plateau before males (Fig. 1D).
These data contrast with previous published figures
that found differences between males and females at
all age points studied [24]. Our levels may show higher
deviations between individuals.
In parallel we have analyzed the level of brain
amyloid deposition at different age by immunohisto-
chemistry as described in the Supplementary Material.
The quantification of plaques showed that males
reached the plateau before females, at 9 months
(p = 0.009), just the opposite of what we found in the
ELISA tests (Fig. 2A–C). Although A concentrations
increased more in females, the number of plaques was
smaller than in males. This observation confirms that
the deposition kinetic varies greatly between the sexes.
We can conclude that APP/PS1 transgenic mice
show slight gender differences in the kinetic of accu-
mulation but not in the final amount of amyloid
accumulated at older age. The number and complex-
ity of the plaques increase exponentially with age,
being surrounded by reactive glia (Fig. 2B). These
mature plaques finally occupied a significant portion of
the brain tissue; the quantification showed no signif-
icant differences; males versus females. Surprisingly
this final accumulation, at least in our colony, doesn’t
imply any significant reduction in the survival rate,
as reported in some APP/PS1 colonies [1, 16]. In
addition, some mice reach surprisingly high ages of
24 months in overall good health. However, we have
observed some bladder malfunction presented as a
swollen bladder that affects differentially both sexes
(Supplementary Fig. 1B). Males showed these prob-
lems from the very beginning of their lives, while
females do not present any before 10 months of age
(Supplementary Fig. 1A). This event could be related
to unknown deposits in the urine that are not A-
positive unless by ELISA (data not shown). Although
changes in bladder innervation have been described in
APP/PS1 mice [25], we can confirm that this event
shows gender differences too.
Finally, we have checked some biochemical param-
eters following molecular markers by Western blot in
brain samples (described in Supplementary Material).
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Fig. 1. A levels in plasma and brain samples of males (blue square) and females (pink triangle) transgenic mice. Levels of plasma A40 (A) and
A42 (B) in mice (from 3 to 15 months) were obtained by ELISA. C) Ratio A42/A40 in plasma from 3 to 15 months. D) A40 burden in brain
samples of transgenic mice from 1 to 15 months. When statistically significant ∗∗p≤ 0.01 (t-test). Western blot analysis of some biochemical
markers in the mice brains; 6 and 15 months, male, female, transgenic and wild type. A and -secretase levels (E), synaptic markers (F) and
kinases (G).
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Fig. 2. Histology analysis of males and females transgenic mice brains from 3 to 15 months. A) Representative images of immunohistochemistry
studies (6e10 antibody). B) Comparison of the increase in A plaques deposition and glial reaction between 3- and 23-months-old mice. A
plaques (in red) marked with 6e10 antibody and glial (in green) marked with GFAP antibody, DAPI in blue was used to stain nuclei. C) Graph
of the percentage of area occupied by plaques obtained by Image J software. When statistically significant ∗∗p≤ 0.01 (t-test).
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Levels of -secretase (BACE), PHF1, GFAP and A
(monomer and oligomer) have been checked in all the
groups analyzed; 6 and 15 months, transgenic and wild-
type (wt), males and females (Supplementary Fig. 1C).
We have compared the levels of some relevant kinases
for tau phosphorylation, such as Akt, GSK3, and Erk
(Fig. 1G); and some synaptic proteins such as PSD95,
p120, p-Synapsin and N-Catenin (Fig. 1F).
It is very relevant that the levels of p-synapsin, p120
and PSD95 are increased in old transgenic females
being higher than transgenic males. Moreover, 15
months transgenic females showed higher levels of
p120 and PSD95 than wt at the same age. Levels of
N-catenin were higher in transgenic females than trans-
genic males at 6 months of age but no differences were
found in older mice with this marker. In general, we
can observe that 6 months mice did not show any mod-
ification in the synaptic markers; however we can see
very increased levels in old transgenic females.
Kinases determination showed different results. Wt
females showed higher levels of pAKT than transgenic
females at 6 months; however pAKT levels were not
modified at 15 months. When we analyze p-Erk we
have found increased levels in old transgenic males
while females showed no differences. Finally, pGSK3
was not modified in any group.
In conclusion, both genders accumulate plaques in
the brain exponentially with age and they both have
detectable levels of A in plasma. However, the evo-
lution of A levels is divergent, so it is tempting to
propose that an “aging factor” differentially affects
male and female specimens in this AD model. These
gender differences may be related to sex hormones;
being even though some hypotheses point to oestrogen
as the main party responsible [26, 27].
Finally, considering the differences shown in this
mice model, we would like to emphasize that these
differences should be taken into account not only for
previously published data but also for future exper-
iments because mixing male and female will result
in confusing or counter-balanced results [8]. In addi-
tion, this opens up the possibility of performing a
wide-ranging analysis of peripheral A in the human
population to try to correlate the amount of A42/A40
with normal aging and AD evolution in both genders.
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